FindTrial
Sign In

A randomized, controlled, split-face clinical trial comparing combination of ProACNE SOLUTION ACTIVE CLEAR with 2.5% benzoyl peroxide versus 2.5% benzoyl peroxide with placebo in the treatment of mild to moderate degree of acne vulgaris

A randomized, controlled, split-face clinical trial comparing combination of ProACNE SOLUTION ACTIVE CLEAR with 2.5% benzoyl peroxide versus 2.5% benzoyl peroxide with placebo in the treatment of mild to moderate degree of acne vulgaris

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20171104001
Enrollment
19
Registered
2017-11-04
Start date
2017-11-06
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mild to moderate degree of acne vulgaris Acne acne vulgaris benzoyl peroxide salicylic acid L&#45

Interventions

salicylic acid&#44
L&#45
carnitine&#44
decylene glycol&#44
licochalcone A,cetyl alcohol&#44
steraric acid&#44
glyceryl monostearate&#44
propylene glycol&#44
sodium lauryl sulfate&#44
propyl praben&#44
perified water (In&#45
house preparation)
Active Comparator Drug,Placebo Comparator Drug
ProACNE SOLUTION ACTIVE CLEAR with 2.5% benzoyl peroxide,2.5% benzoyl peroxide with placebo (Hydrophilic cream)

Sponsors

Beiersdorf (Thailand) Co., Ltd
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: - age 18 - 40 years old - mild to moderate degree of acne vulgaris, according to Leeds revised acne grading

Exclusion criteria

Exclusion criteria: - pregnant or breast-feeding woman - allergic to benzoyl peroxide or any ingredient of ProACNE SOLUTION ACTIVE CLEAR (salicylic acid, L-carnitine, decylene glycol, licochalcone A) - deny to discontinue topical therapy of acne more than 14 days before starting treatment. - denial to discontinue topical therapy of acne more than 14 days before starting treatment. - denial to discontinue systemic therapy of acne more than 28 days before starting treatment. - irregular menstruation or known case of PCOS

Design outcomes

Primary

MeasureTime frame
number of inflammatory acne lesions which decrease within 8 weeks 1,2,4,8 week Examination of the facial skin—

Secondary

MeasureTime frame
degree of acne severity 1,2,4,8 week Examination of the facial skin,skin biophysical changes (including TEWL, sebum, hydration in the skin) 1,2,4,8 week multi probe system Cutometer® dual MPA580,patient satisfaction score 1,2,4,8 week satisfaction score—

Countries

Thailand

Contacts

Public ContactPravit Asawanonda

Faculty of Medicine. Chulalongkorn University

fibrosis@gmail.com081-812-9393

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026